Drugs / Yttrium-90
Yttrium-90
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05195710 | Nov 2022 → Mar 2028 expected | metastatic neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04518748 | Sep 2020 → May 2028 expected | liver cancer | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06725121 | Dec 2024 → Jun 2031 expected | hepatocellular carcinoma, invasive carcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06555133 | Apr 2025 → Sep 2026 expected | colorectal carcinoma | Brown University | Recruiting | No outcome recorded |
| Phase 2 | NCT02167711 | Sep 2014 → Jan 2023 | intrahepatic cholangiocarcinoma | Chinese University of Hong Kong | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05620771 Background | Nov 2022 → Jul 2040 expected | hepatocellular carcinoma | Northwestern University | Recruiting | No outcome recorded |
| Phase 2 | NCT01381211 Comparator | Sep 2011 → Mar 2018 | hepatocellular carcinoma | University Hospital, Ghent | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yttrium-90 | “Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used” NCT01381211 ↗6“Therasphere® (Yttrium-90)” NCT05620771 ↗ |
| Known as | Therasphere | “Therasphere® (Yttrium-90)” NCT05620771 ↗ |
| Known as | Y-90 | “Y-90 radioembolization one or both hemilivers based on distribution of disease” NCT06555133 ↗4“Yttrium-90 (Y-90) resin microspheres” NCT05195710 ↗ “Therasphere® (Y-90)” NCT05620771 ↗ “Yttrium-90 (Y-90)” NCT06725121 ↗ |
| Modality | Other / unclassified | “Radioactive isotope Y-90” NCT04518748 ↗ |
| Route | Other | “Yttrium-90 radioembolization ((90)Y-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90” PMID 22913492 ↗ Aug 2012 |